CLAIMS

1. A compound characterized by having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, having the structure:



(I)

wherein:

A is selected from the group consisting of an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl, an optionally substituted aryl(C_{1-2} alkyl), an optionally substituted heteroaryl and an optionally substituted heterocyclyl;

W is O, S, C=O, C=S, NR^{3a3}, S=O, $S(=O)_2$ or $-C(R^{1a1})(R^{1a2})-$;

V is N or CH;

E is C or N; provided that when E is N, then R^{2a1} is absent;

Z is selected from the group consisting of , , ,  and ;

Y is selected from the group consisting of an optionally substituted acylalkyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted heterocyclyl;

<u>--------</u> between X^2 and X^3 represents a single or double bond between X^2 and X^3;

wherein when <u>------</u> is a double bond, then X^1 is NR^{3a1} or $CR^{3a2}R^6$, X^2 is N (nitrogen) or CR^{7a1}, and X^3 is N (nitrogen) or CR^4; and when <u>--------</u> is a single bond, then X^1 is NR^{3a1} or $CR^{3a2}R^6$, X^2 is O, NR^7, C(=O) or $C(R^{7a2})(R^{7a3})$, and X^3 is NR^4, C(=O), CR^4R^8 or $CH_2CH_2C(=O)$; or

X^1, X^2 and X^3 are each independently C (carbon), N (nitrogen), O (oxygen) or C(=O), and form a mono-cyclic ring selected from the group consisting of an optionally substituted mono-cyclic heteroaryl and an optionally substituted mono-cyclic heterocyclyl by joining X^1 and X^3 together; and provided that at least one of X^1, X^2 and X^3 comprises a nitrogen atom, with the proviso that the valencies of X^1, X^2 and X^3 are satisfied with a substituent selected from the group consisting of hydrogen and an optionally substituted C_{1-4} alkyl; and X^1, X^2 and X^3 are uncharged;

L^1 is $-C(R^{17})_2-$, $-C(R^{18})_2C(R^{18a1})_2-$, $-C(R^{18a2})=C(R^{18a3})-$ or $-C(R^{19})_2N(R^{19a1})-$;

L^2 is $-C(R^{20})_2-$, $-N(R^{21})-$, S, or O;

each L^3 is independently $-C(R^{22})_2-$, $-C(R^{23})_2C(R^{23a1})_2-$ or $-C(R^{23a2})=C(R^{23a3})-$;

provided that when L^1 is $-C(R^{19})_2N(R^{19a1})-$, then L^2 is $-C(R^{20})_2-$;

R^1 is hydrogen or an unsubstituted C_{1-4} alkyl;

R^{1a1} and R^{1a2} are each independently hydrogen, hydroxy or an unsubstituted C_{1-4} alkyl;

R^2 and R^{2a1} are each independently selected from the group consisting of hydrogen, an optionally substituted C_{1-4} alkyl, alkoxyalkyl, aminoalkyl, hydroxyalkyl, hydroxy, an optionally substituted aryl(C_{1-6} alkyl), an optionally substituted heteroaryl(C_{1-6} alkyl) and an optionally substituted heterocyclyl(C_{1-6} alkyl); or

R^1 and R^2, together with the atoms to which they are attached, are joined to form an optionally substituted 5-membered heterocyclic ring or an optionally substituted 6-membered heterocyclic ring, R^{2a1} is selected from the group consisting of hydrogen, an optionally substituted C_{1-4} alkyl, alkoxyalkyl, aminoalkyl, hydroxyalkyl, hydroxy, an optionally substituted aryl(C_{1-6} alkyl), an optionally substituted heteroaryl(C_{1-6} alkyl) and an optionally substituted heterocyclyl(C_{1-6} alkyl);

R^{3a1}, R^{3a2} and R^{3a3} are each independently hydrogen or an unsubstituted C_{1-4} alkyl;

R^4 is selected from the group consisting of hydrogen, an optionally substituted C_{1-8} alkyl, an optionally substituted C_{2-8} alkenyl, an optionally substituted C_{2-8} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted C_{3-6} cycloalkyl(C_{1-6} alkyl), an optionally substituted aryl(C_{1-6} alkyl), an optionally substituted heteroaryl(C_{1-6} alkyl), an optionally substituted heterocyclyl(C_{1-6} alkyl), halo(C_{1-8} alkyl), an optionally substituted hydroxyalkyl, an optionally substituted alkoxyalkyl and cyano;

R^6, R^7, and R^{7a1} are each independently hydrogen or an unsubstituted C_{1-4} alkyl;

R^{7a2} and R^{7a3} are each independently hydrogen or an unsubstituted C_{1-4} alkyl;

R^8 is hydrogen or optionally substituted C_{1-4} alkyl;

R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15} and R^{16} are each independently hydrogen or an unsubstituted C_{1-4} alkyl; or R^9 and R^{10}, R^{11} and R^{12}, R^{13} and R^{14}, and R^{15} and R^{16}, are each independently taken together form an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl or an optionally substituted heterocyclyl; and

each R^{17}, each R^{18}, each R^{18a1}, R^{18a2}, R^{18a3}, each R^{19}, R^{19a1}, each R^{20}, R^{21}, each R^{22}, each R^{23}, each R^{23a1}, R^{23a2} and R^{23a3} are each independently hydrogen or an unsubstituted C_{1-4} alkyl;

provided that when X^1 is NR^{3a1}, X^2=X^3 is N=CR^4, Y is an optionally substituted indolyl, then R^4 is selected from the group consisting of hydrogen, cyano, an optionally substituted C_{2-6} alkyl, an optionally substituted acylalkyl, an optionally substituted hydroxyalkyl, an optionally substituted alkoxy(alkyl), an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{2-6} alkynyl, haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{3-6} cycloalkyl(C_{1-6} alkyl), an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted aryl(C_{1-6} alkyl), an optionally substituted heteroaryl(C_{1-6} alkyl) and an optionally substituted heterocyclyl(C_{1-6} alkyl); and

provided that when X^1 is NR^{3a1}, X^2=X^3 is N=CR^4, Y is 

, then R^4 is selected from the group consisting of cyano, halo(C_{1-8}alkyl), an optionally substituted acylalkyl, an optionally substituted C_{1-8} alkyl, an optionally substituted hydroxyalkyl, an optionally substituted alkoxy(alkyl), an optionally substituted C_{2-8} alkenyl, an optionally substituted C_{2-8} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{3-6} cycloalkyl(C_{1-6} alkyl), an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted aryl(C_{1-6} alkyl), an optionally substituted heteroaryl(C_{1-6} alkyl) and an optionally substituted heterocyclyl(C_{1-6} alkyl).

2. The compound of Claim 1, wherein ------ between X^2 and X^3 is a double bond, X^2 is N (nitrogen) or CR^{7a1}, and X^3 is N (nitrogen) or CR^4.

3. The compound of Claim 1, wherein ------ between X^2 and X^3 is a single bond, X^2 is O, NR^7, C(=O) or $C(R^{7a2})(R^{7a3})$, and X^3 is NR^4, C(=O) or CR^4R^8.

4. The compound of Claim 1, wherein X^1, X^2 and X^3 are each independently C (carbon), N (nitrogen), O (oxygen) or C(=O), and form a mono-cyclic ring selected from the group consisting of an optionally substituted mono-cyclic heteroaryl and an optionally substituted mono-cyclic heterocyclyl by joining X^1 and X^3 together; and provided that at least one of X^1, X^2 and X^3 comprises a nitrogen atom; with the proviso that the valencies of X^1, X^2 and X^3 are satisfied with a substituent selected from the group consisting of hydrogen and an optionally substituted C_{1-4} alkyl; and X^1, X^2 and X^3 are uncharged.

5. The compound of any one of Claims 1-4, wherein W is C=O.

6. The compound of any one of Claims 1-4, wherein W is O, S, C=S, NR^{3a3}, S=O, $S(=O)_2$ or $-C(R^{1a1})(R^{1a2})-$.

7. The compound of Claim 6, wherein both R^{1a1} and R^{1a2} are hydrogen.

8. The compound of Claim 6, wherein at least one of R^{1a1} and R^{1a2} is hydrogen and the other of R^{1a} and R^{1a2} is hydroxy or an unsubstituted C_{1-4} alkyl.

9. The compound of any one of Claims 1-8, wherein V is NH or N(an un substituted C_{1-4} alkyl).

10. The compound of any one of Claims 1-8, wherein V is CH.

11. The compound of any one of Claims 1-10, wherein E is C.

12. The compound of Claim 11, wherein both R^2 and R^{2a1} are hydrogen.

13. The compound of Claim 11, wherein R^2 is hydrogen and R^{2a1} is an optionally substituted C_{1-4} alkyl, an optionally substituted aryl(C_{1-6} alkyl), an optionally substituted heterocyclyl(C_{1-6} alkyl), an alkoxyalkyl, an aminoalkyl, a hydroxyalkyl or hydroxy.

14. The compound of any one of Claims 1-10, wherein E is N, provided that R^{2a1} is absent.

15. The compound of any one of Claims 2-3, 5-10 or 12-13, wherein a compound of Formula (I) is a compound of Formula (Ia):



(Ia).

16. The compound of Claim 15, wherein ------- between X^2 and X^3 represents a double bond and  is  or .

17. The compound of Claim 15, wherein X^1, X^2 and X^3 are each independently C (carbon), N (nitrogen), O (oxygen) or C(=O), and form a mono-cyclic ring selected from the group consisting of an optionally substituted mono-cyclic heteroaryl and an optionally substituted mono-cyclic heterocyclyl by joining X^1 and X^3 together; and provided that at least one of X^1, X^2 and X^3 comprises a nitrogen atom; with the proviso that the valencies of X^1, X^2 and X^3 are satisfied with a substituent selected from the group consisting of hydrogen and an optionally substituted C_{1-4} alkyl; and X^1, X^2 and X^3 are uncharged.

18. The compound of Claim 15, wherein ------- between X^2 and X^3 represents a single bond and  is , , , ,  or .

19. The compound of any one of Claims 2-3, 5-9 or 12-13, wherein a compound of Formula (I) is a compound of Formula (Ib):  (Ib).

20. The compound of any one of Claims 1, 12 or 13, wherein a compound of Formula (I) is a compound of Formula (Ic):



(Ic)

wherein: the dotted curved line between X^1 and X^3 indicates a mono-cyclic ring selected from the group consisting of an optionally substituted mono-cyclic heteroaryl and an optionally substituted mono-cyclic heterocyclyl by joining X^1 and X^3 together; wherein X^1, X^2 and X^3 are each independently C (carbon), N (nitrogen), O (oxygen) or C(=O); and provided that at least one of X^1, X^2 and X^3 comprises a nitrogen atom; with the proviso that the valencies of X^1, X^2 and X^3 are satisfied with a substituent selected from the group consisting of hydrogen and an optionally substituted C_{1-4} alkyl; and X^1, X^2 and X^3 are uncharged.

21. The compound of Claim 20, wherein the ring is an optionally substituted 5 membered mono-cyclic heteroaryl or an optionally substituted 5 membered mono-cyclic heterocyclyl.

22. The compound of Claim 20, wherein the ring is an optionally substituted 6 membered mono-cyclic heteroaryl or an optionally substituted 6 membered mono-cyclic heterocyclyl.

23. The compound of any one of Claims 20-22, wherein X^1 is C, X^2 is N and X^3 is C.

24. The compound of any one of Claims 20-22, wherein the ring or ring system is selected from the group consisting of: an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally

substituted , an optionally substituted , an optionally substituted  and an optionally substituted ; wherein R^{a4} and R^{a5} are each independently hydrogen or an unsubstituted C_{1-6} alkyl.

25. The compound of any one of Claims 20-22, wherein the ring or ring system is selected from the group consisting of: an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted  and an optionally substituted ; wherein R^{6a1}, R^{6a2} and R^{6a3} are each independently hydrogen or an unsubstituted C_{1-6} alkyl.

26. The compound of any one of Claims 1, 12 or 13, wherein a compound of Formula (I) is a compound of Formula (Id):



(Id)

wherein: R^{9a}, R^{10a} and R^{11a} are each be independently selected from the group consisting of hydrogen, halogen, hydroxy, an optionally substituted C_{1-8} alkyl, an optionally substituted C_{2-8} alkenyl, an optionally substituted C_{2-8} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted hydroxyalkyl, an optionally substituted C_{1-8} alkoxy, an optionally substituted alkoxyalkyl, amino, mono-substituted amino, di-substituted amino, halo(C_{1-8} alkyl), haloalkyl and an optionally substituted C-carboxy.

27. The compound of any one of Claims 1, 12 or 13, wherein a compound of Formula (I) is a compound of Formula (Ie):



(Ie).

28. The compound of any one of Claims 1, 5-10, 12 or 13, wherein a compound of Formula (I) is a compound of Formula (If):



(If)

wherein: W is O (oxygen), S (sulfur), NR^{3a3}, S=O, $S(=O)_2$ or $-C(R^{1a1})(R^{1a2})-$, and V is N or CH_2.

29. The compound of any one of Claims 1, 5-10, 12 or 1, wherein a compound of Formula (I) is a compound selected from the group consisting of a compound of Formula (Ig), a compound of Formula (Ih), a compound of Formula (Ii) and a compound of Formula (Ij):



(Ig)



(Ih)



(Ii)



(Ij)

30. The compound of any one of Claims 1-29, wherein A is an optionally substituted aryl.

31. The compound of Claim 30, wherein A is an optionally substituted phenyl.

32. The compound of any one of Claims 1-29, wherein A is an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl an optionally substituted heteroaryl or an optionally substituted heterocyclyl.

33. The compound of any one of Claims 1-32, wherein Y is an optionally substituted aryl.

34. The compound of any one of Claims 1-32, wherein Y is an optionally substituted mono-cyclic heteroaryl or an optionally substituted bi-cyclic heteroaryl.

35. The compound of any one of Claims 1-32, wherein Y is an optionally substituted heterocyclyl.

36. The compound of any one of Claims 1-32, wherein Y is an optionally substituted acylalkyl, an optionally substituted cycloalkyl or an optionally substituted cycloalkenyl.

37. The compound of Claim 1, wherein the compound is selected from the group consisting of: 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 242, 244, 245, 246A, 246B, 247, 300, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 415, 416, 417, 419, 422, 423, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 437, 438, 439, 440, 441, 442, 443, 444, 445, 448A, 448B, 449, 450, 453, 454, 455A, 455B,

456, 457, 458A, 458B, 459, 460, 461, 462A, 462B, 463A, 463B, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 400-1, 400-2, 400-3, 400-4, 400-5, 400-6, 400-7, 400-8, 400-9, 400-10, 400-11, 400-12, 400-13, 400-14, 400-15, 400-16, 400-17, 400-18, 400-19, 400-20, 400-21, 400-22, 400-24, 400-25, 400-26, 400-27, 400-28, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514A, 514B, 600, 601, 602, 603A, 603B, 604, 605, 606, 650, 651, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 901, 1206, 1352, 2300, 2301, 2302, 2303, 2304, 2400, 2401, 4105, 4304, 4305, 4306 , 4307, 4308, 4309, 4310, 4311, 4312, 4313, 4314, 1200, 1202, 1204, 1209, 1211, 1213, 1214, 1216, 1217, 1220, 1221, 1223, 1224, 1225, 1226, 1227, 1230, 1231, 1232, 1233, 1234, 1235, 1236, 1237, 1238, 1239, 1242, 1243, 1244, 1245, 1246, 1247, 1248, 1249, 1250, 1251, 1252, 1253, 1255, 1256, 1257, 1258, 1300, 1301, 1302, 1303, 1304, 1307, 1308, 1309, 1310, 1311, 1312, 1313, 1314, 1315, 1316, 1317, 1318, 1319, 1320, 1321, 1322, 1323, 1325, 1326, 1327, 1328, 1329, 1330, 1331, 1332, 1333, 1334, 1335, 1336, 1340, 1341, 1343, 1344, 1345, 1346, 1359, 1360, 1401, 1402, 1403, 1404, 1405, 1501, 1502, 1503, 1504, 1505, 1506, 1507, 1508, 1509, 1510, 1511, 1512, 1513, 1514, 1515, 1516, 1517, 1518, 1519, 1520, 1521, 1522, 1523, 1524, 1525, 1526, 1527, 1528, 1529, 1530, 1531, 1532, 1533, 1534, 1535, 1536, 1537, 1538, 1539, 1540, 1541, 1601, 1602, 1603, 1604, 1605, 1606, 1607, 1608, 1609, 1610, 1611, 1612, 1613, 1614, 1615, 1616, 1617, 1618, 1619, 1620, 1621, 1622, 1623, 1800, 1802, 1803, 1804, 1805, 1806, 1807, 1808, 1809, 1810, 1811, 1812, 1813, 1814, 1815, 1816, 1817, 1818, 1819, 1820, 1821, 1822, 1823, 1824, 1825, 1826, 1829, 1830, 1831, 1832, 1833, 1834, 1835, 1836, 1837, 1838, 1839, 1900, 1901, 1902, 1903, , 2000, 2100, 2101, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2111, 2112, 2113, 2114, 2115, 2504, 2506, 2507, 2508, , 2601, 2602, 2603, 2604, 2605, 2613, 2615, 2617, 2618, 2619, 2620, 2621, 2622, 2624, 2626, 2627, 2638, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2654, 3302, 3800, 3903, 4002, 4201, 4202, 4203, 4204, 4205, 4206, 4207, 4208, 4209, 4210, 4212 and 4216.

38. The compound of Claim 1, wherein the compound is selected from the group consisting of: 840, 1100, 1101, 1201, 1205, 1210, 1215, 1219, 1222, 1228, 1240, 1241, 2204, 2205, 2305, 2800, 2801, 3200, 3401, 3500, 3501, 3900, 4303, 900, 902, 903, 904, 908, 910, 917, 1000, 2803, 3300, 4302, 239, 240, 241, 2306 and 2802.

39. A compound of Formula (II), or a pharmaceutically acceptable salt thereof, having the structure:

$$A^b—L^b—Y^b \quad \text{(II)}$$

wherein: L^b is selected from the group consisting of:



(IIa),



(IIb),



(IIc),



(IId),



(IIe),



(IIf),



(IIg),



(IIh),



(IIi),



(IIj),



(IIk),


(III) and


(IIm);

A^b is an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl, an optionally substituted aryl(C_{1-2} alkyl), an optionally substituted heteroaryl or an optionally substituted heterocyclyl;

Y^b is an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl or an optionally substituted heterocyclyl;

when L^b is Formula (IIc), -------- between X^{2b} and X^{3b} represents a single or double bond between X^{2b} and X^{3b}, when -------- between X^{2b} and X^{3b} is a double bond, then X^{1b} is independently NR^{3b} or $CR^{3b1}R^{3b2}$, X^{2b} is N (nitrogen) or CR^{7b1}, and X^{3b} is N (nitrogen) or CR^{4b}; when -------- between X^{2b} and X^{3b} is a single bond, then X^{1b} is independently NR^{3b} or $CR^{3b1}R^{3b2}$, X^{2b} is O (oxygen), NR^{7b} or $C(R^{7b2})(R^{7b3})$, and X^{3b} is NR^{4b}, C(=O) or $CR^{4b}R^{8b}$; or

X^{1b}, X^{2b} and X^{3b} are each independently C (carbon), N (nitrogen). O (oxygen) or C(=O), and form a ring or ring system selected from the group consisting of an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted heterocyclyl by joining X^{1b} and X^{3b} together; with the proviso that the valencies of X^{1b}, X^{2b} and X^{3b} are satisfied with a substituent selected from the group consisting of hydrogen and an optionally substituted C_{1-4} alkyl, and X^{1b}, X^{2b} and X^{3b} are uncharged;

X^{4b} is NR^{6b1} or $C(R^{6b2})_2$;

X^{5b} is NR^{6b3} or $C(R^{6b4})_2$;

X^{6b} is NR^{6b5} or C(=O);

X^{7b} is $NR^{6b6}CH_2$ or -C(=O)-an optionally substituted pyridinyl-;

Z^b is N or CH;

R^{1b} is hydrogen or an unsubstituted C_{1-4} alkyl;

R^{1b2} is hydrogen or an unsubstituted C_{1-4} alkyl;

when L^b is Formula (IIg), then Y^b is absent;

when ------- of Formula (III) is a single bond, then R^{1b3} is hydroxy; when ------- of Formula (III) is a double bond, then R^{1b3} is O (oxygen);

R^{2b} and R^{2b1} are each independently hydrogen or an optionally substituted C_{1-4} alkyl, and when more than one R^{2b} and/or more than one R^{2b1} are present, each R^{2b} and each R^{2b1} is the same or different;

R^{3b}, R^{3b1} and R^{3b2} are each independently hydrogen or an unsubstituted C_{1-4} alkyl;

R^{4b} is hydrogen, an optionally substituted C_{1-4} alkyl or an optionally substituted alkoxyalkyl;

R^{5b} and R^{5b1} are each independently hydrogen or hydroxy;

R^{6b1}, each R^{6b2}, R^{6b3}, each R^{6b4}, R^{6b5} and R^{6b6} are each independently hydrogen or an unsubstituted C_{1-4} alkyl;

R^{7b} and R^{7b1} are each independently be hydrogen or an unsubstituted C_{1-4} alkyl;

R^{7b2} and R^{7b3} are each independently hydrogen or an unsubstituted C_{1-4} alkyl; or R^{7b2} and R^{7b3} together form =O;

R^{8b} is hydrogen or an unsubstituted C_{1-4} alkyl;

R^{9b} and R^{10b} are each independently an unsubstituted C_{1-4} alkyl, an unsubstituted C_{1-4} alkenyl or an unsubstituted C_{1-4} alkoxy; or

R^{9b} and R^{10b} are taken together to form an unsubstituted aryl, an unsubstituted heteroaryl or an optionally substituted heterocyclyl;

ring B is an optionally substituted  or an optionally substituted ;

ring B1 is an optionally substituted mono-cyclic cycloalkyl, an optionally substituted phenyl, an optionally substituted mono-cyclic heteroaryl or an optionally substituted mono-cyclic heterocyclyl;

ring B2 is an optionally substituted heteroaryl;

ring B3 is an optionally substituted pyridinyl;

ring B4 is an optionally substituted heteroaryl or an optionally substituted heterocyclyl;

ring B5 is an optionally substituted pyridinyl;

ring B6 is an optionally substituted pyridinyl;

ring B7 is an optionally substituted heterocyclyl;

$m1^b$ and $m2^b$ are each independently 0 or 1; provided that at least one of $m1^b$ and $m2^b$ is 1;

$m3^b$ is 0 or 1; and

n^b is 2 or 3.

40. The compound of Claim 39, wherein the compound is selected from the group consisting of: 1339, 4101, 3100, 3101, 3102, 3103, 3000 and 3001.

41. A pharmaceutical composition comprising an effective amount of a compound of any one of Claims 1-40, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, excipient, or combination thereof.

42. Use of an effective amount of a compound of any one of Claims 1-40, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for ameliorating or treating a paramyxovirus infection.

43. Use of an effective amount of a compound of any one of Claims 1-40, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for inhibiting replication of a paramyxovirus.

44. The use of any one of Claims 42-43, wherein the paramyxovirus infection is a human respiratory syncytial virus infection.

45. The use of any one of Claims 42-43, wherein the paramyxovirus infection is a human respiratory syncytial virus infection, and further comprising the use of an effective amount of one or more anti RSV-agents.

46. The use of Claim 45, wherein the one or more anti-RSV agents is selected from the group consisting of ribavirin, palivizumab, RSV-IGIV, ALN-RSV01, BMS-433771, RFI-641, RSV604, MDT-637, BTA9881, TMC-353121, MBX-300 and YM-53403.

CLAIMS

1. A compound characterized by having the structure of Formula (Ib) or Formula (Ic), or a pharmaceutically acceptable salt thereof, having the structure:


(Ib)


(Ic);

wherein X^1, X^2 and X^3 are each independently C (carbon), N (nitrogen), O (oxygen) or C(=O),



and in Formula (Ic) the dotted line between X^1 and X^3 of indicates a mono-cyclic ring selected from the group consisting of an optionally substituted 5 membered mono-cyclic heteroaryl, an optionally substituted 6 membered mono-cyclic heteroaryl, an optionally substituted 5 membered mono-cyclic heterocyclyl and an optionally substituted 6 membered mono-cyclic heterocyclyl by joining X^1 and X^3 together; with the proviso that the valencies of X^1, X^2 and X^3 are satisfied with a substituent selected from the group consisting of hydrogen and an optionally substituted C_{1-4} alkyl; and X^1, X^2 and X^3 are uncharged;

wherein:

A is selected from the group consisting of an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted C_{6-10} aryl, an optionally substituted C_{6-10} aryl(C_{1-2} alkyl), an optionally substituted heteroaryl and an optionally substituted heterocyclyl;

when the compound is a compound of Formula (Ib), Y is selected from the group consisting of a substituted phenyl, wherein the phenyl is substituted with one or more substituents selected from the group consisting of cyano, an optionally substituted C_{1-4} alkyl, an unsubstituted C_{2-4} alkenyl, an unsubstituted C_{2-4} alkynyl, an optionally substituted C_{6-10} aryl, an optionally substituted 5 or 6 membered heteroaryl, an optionally substituted 5 or 6 membered heterocyclyl, C_{1-4} haloalkyl, haloalkoxy, an unsubstituted acyl, an optionally substituted –C-

carboxy, an optionally substituted -C-amido, sulfonyl, mono-C_{1-4} alkyl amino, di-C_{1-4} alkyl amino and ,

an optionally substituted monocyclic heteroaryl selected from the group consisting of an optionally substituted imidazole, a substituted furan, a substituted thiophene, an optionally substituted pyrrole, a substituted pyrimidine, an optionally substituted pyrazine, a substituted pyridine, an optionally substituted oxazole and an optionally substituted isoxazole,

an optionally substituted bicyclic heteroaryl selected from the group consisting of an optionally substituted benzothiophene, an optionally substituted benzofuran, a substituted indole, an optionally substituted quinoline, an optionally substituted isoquinoline, an optionally substituted benzooxazole, an optionally substituted benzoisoxazole, an optionally substituted benzoisothiazole, an optionally substituted benzothiazole, an optionally substituted benzoimidazole, an optionally substituted benzotriazole, an optionally substituted 1H-indazole, an optionally substituted 2H-indazole, an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted  and an optionally substituted ;

wherein when Y of Formula (Ib) is a substituted monocyclic heteroaryl, the monocyclic heteroaryl is substituted with one or more substituents selected from the group consisting of halo, a substituted C_{1-4} alkyl, an optionally substituted phenyl and an unsubstituted acyl;

wherein when Y of Formula (Ib) is a substituted bicyclic heteroaryl, the bicyclic heteroaryl is substituted with one or more substituents selected from the group consisting of halo, a substituted C_{1-4} alkyl, an optionally substituted phenyl, hydroxy, C_{1-4} alkoxy, an unsubstituted acyl, carbonyl, cyano, amino, mono-C_{1-4} alkyl amino and di-C_{1-4} alkyl amino; and

when the compound is a compound of Formula (Ic), Y is selected from the group consisting of an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted C_{6-10} aryl, an optionally substituted heteroaryl and an optionally substituted heterocyclyl;

R^1 is hydrogen or an unsubstituted C_{1-4} alkyl;

R^2 and R^{2a1} are each independently selected from the group consisting of hydrogen, an optionally substituted C_{1-4} alkyl, alkoxyalkyl, aminoalkyl, hydroxyalkyl, hydroxy, an optionally substituted C_{6-10} aryl(C_{1-6} alkyl), an optionally substituted heteroaryl(C_{1-6} alkyl) and an optionally substituted heterocyclyl(C_{1-6} alkyl); or

R^1 and R^2, together with the atoms to which they are attached, are joined to form an optionally substituted 5-membered heterocyclic ring or an optionally substituted 6-membered heterocyclic ring, R^{2a1} is selected from the group consisting of hydrogen, an optionally substituted C_{1-4} alkyl, alkoxyalkyl, aminoalkyl, hydroxyalkyl, hydroxy, an optionally substituted C_{6-10} aryl(C_{1-6} alkyl), an optionally substituted heteroaryl(C_{1-6} alkyl) and an optionally substituted heterocyclyl(C_{1-6} alkyl);

R^{3a1} is hydrogen or an unsubstituted C_{1-4} alkyl;

R^4 is selected from the group consisting of hydrogen, an optionally substituted C_{1-8} alkyl, an optionally substituted C_{2-8} alkenyl, an optionally substituted C_{2-8} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{6-10} aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted C_{3-6} cycloalkyl(C_{1-6} alkyl), an optionally substituted C_{6-10} aryl(C_{1-6} alkyl), an optionally substituted heteroaryl(C_{1-6} alkyl), an optionally substituted heterocyclyl(C_{1-6} alkyl), halo(C_{1-8} alkyl), an optionally substituted hydroxyalkyl, an optionally substituted alkoxyalkyl and cyano;

wherein when a group is optionally substituted, unless otherwise specified, the group may be substituted with one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acylalkyl, alkoxyalkyl, aminoalkyl, amino acid, C_{6-10} aryl, heteroaryl, heterocyclyl, C_{6-10} aryl(alkyl), heteroaryl(alkyl), heterocyclyl(alkyl), hydroxy, hydroxyalkyl, acyl, cyano, halogen, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, azido, nitro, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido, an amino, a mono-substituted amino and a di-substituted amino;

wherein "heteroaryl" refers to a monocyclic or multicyclic aromatic ring system, wherein the ring system has a fully delocalized pi-electron system and contains one or more heteroatoms selected from nitrogen, oxygen and sulfur, and wherein the heteroaryl contains 4 to 14 atoms in the ring(s); and

wherein "heterocyclyl" refers to a 3 to 18-membered monocyclic, bicyclic, and tricyclic ring system wherein carbon atoms together with from 1 to 5 heteroatoms selected from nitrogen, oxygen and sulfur constitute said ring system; wherein the heterocycle may optionally contain one or more unsaturated bonds situated in such a way, however, that a fully delocalized pi-electron system does not occur throughout all the rings; wherein the heterocycle may further contain one or more carbonyl or thiocarbonyl functionalities, so as to make the definition include oxo-systems and thio-systems; wherein when composed of two or more rings, the rings may be joined together in a fused fashion; and wherein any nitrogens in the heterocyclyl may be quaternized.

2. The compound of Claim 1, wherein R^1 is hydrogen.

3. The compound of Claim 1, wherein R^1 is an unsubstituted C_{1-4} alkyl.

4. The compound of any one of Claims 1-3, wherein both R^2 and R^{2a1} are hydrogen.

5. The compound of any one of Claims 1-3, wherein R^2 is hydrogen; and R^{2a1} is an unsubstituted C_{1-4} alkyl.

6. The compound of any one of Claims 1-3, wherein R^2 is hydrogen; and R^{2a1} is a substituted C_{1-4} alkyl.

7. The compound of Claim 1, wherein R^2 is hydrogen and R^{2a1} is an optionally substituted C_{6-10} aryl(C_{1-6} alkyl), an optionally substituted heterocyclyl(C_{1-6} alkyl), an

alkoxyalkyl, an aminoalkyl or a hydroxyalkyl; or R^{2a1} is hydrogen and R^1 and R^2 are joined together with the atoms to which they are attached to form an optionally substituted 5 membered heterocyclyl or an optionally substituted 6 membered heterocyclyl.

8. The compound of any one of Claims 1-3, wherein R^2 is hydrogen and R^{2a1} is hydroxy.

9. The compound of any one of Claims 1-8, wherein a compound of Formula (I) is a compound of Formula (Ib).

10. The compound of any one of Claims 1-8, wherein a compound of Formula (I) is a compound of Formula (Ic).



11. The compound of Claim 10, wherein the in Formula (Ic) is an optionally substituted 5 membered mono-cyclic heteroaryl.



12. The compound of Claim 10, wherein the in Formula (Ic) is an optionally substituted 5 membered mono-cyclic heterocyclyl.



13. The compound of Claim 10, wherein the in Formula (Ic) is an optionally substituted 6 membered mono-cyclic heteroaryl.



14. The compound of Claim 10, wherein the in Formula (Ic) is an optionally substituted 6 membered mono-cyclic heterocyclyl.

15. The compound of any one of Claims 11-14, wherein X^1 is C, X^2 is N and X^3 is C.

16. The compound of any one of Claims 11-14, wherein X^1 is N, X^2 is N and X^3 is C; or X^1 is N, X^2 is C(=O) and X^3 is N.

17. The compound of Claim 10, wherein the  in Formula (Ic) is selected from the group consisting of: an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted ; wherein R^{a4} and R^{a5} are each independently hydrogen or an unsubstituted C_{1-6} alkyl.

18. The compound of Claim 10, wherein the  in Formula (Ic) is selected from the group consisting of: an optionally substituted , an

optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted  and an optionally substituted ; wherein R^{6a1}, R^{6a2} and R^{6a3} are each independently hydrogen or an unsubstituted C_{1-6} alkyl.

19. The compound of any one of Claims 1-8, wherein the compound of Formula (Ic) is a compound of Formula (Id):



(Id)

wherein: R^{9a}, R^{10a} and R^{11a} are each independently selected from the group consisting of hydrogen, halogen, hydroxy, an optionally substituted C_{1-8} alkyl, an optionally substituted C_{2-8} alkenyl, an optionally substituted C_{2-8} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{6-10} aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted hydroxyalkyl, an optionally substituted C_{1-8} alkoxy, an optionally substituted alkoxyalkyl, amino, mono-substituted amino, di-substituted amino, halo(C_{1-8} alkyl) and an optionally substituted C-carboxy.

20. The compound of Claim 19, wherein R^{9a} is selected from the group consisting of hydrogen, hydroxy, an optionally substituted C_{1-8} alkyl, an optionally substituted C_{1-8} alkoxy, an optionally substituted alkoxyalkyl, mono-substituted amino and di-substituted amino.

21. The compound of Claim 19 or 20, wherein R^{10a} is selected from the group consisting of hydrogen, halogen, an optionally substituted C_{1-8} alkyl, an optionally substituted C_{2-8} alkenyl, an optionally substituted C_{2-8} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{6-10} aryl, an optionally substituted 6 membered heterocyclyl, an optionally substituted hydroxyalkyl, an optionally substituted C_{1-8} alkoxy, mono-substituted amino, di-substituted amino, halo(C_{1-8} alkyl) and an optionally substituted C-carboxy.

22. The compound of any one of Claims 19-21, wherein R^{11a} is selected from the group consisting of hydrogen, hydroxy and an optionally substituted C_{1-8} alkoxy.

23. The compound of any one of Claims 1-9, wherein R^{3a1} is hydrogen.

24. The compound of any one of Claims 1-9, wherein R^{3a1} is unsubstituted C_{1-4} alkyl.

25. The compound of any one of Claims 1-9 or 23-24, wherein R^4 is selected from the group consisting of hydrogen, an optionally substituted C_{1-8} alkyl, an optionally substituted C_{2-8} alkenyl, an optionally substituted C_{2-8} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted phenyl, an optionally substituted heteroaryl, an unsubstituted C_{3-6} cycloalkyl(C_{1-6} alkyl), an unsubstituted aryl(C_{1-6} alkyl), halo(C_{1-8} alkyl), an unsubstituted hydroxyalkyl, an unsubstituted alkoxyalkyl and cyano.

26. The compound of Claim 25, wherein R^4 is hydrogen.

27. The compound of Claim 25, wherein R^4 is an optionally substituted C_{1-8} alkyl.

28. The compound of Claim 27, wherein R^4 is an unsubstituted C_{1-8} alkyl.

29. The compound of any one of Claims 1-9 or 23-28, wherein A of Formula (Ib) is selected from the group consisting of:

an optionally substituted C_{3-8} monocyclic cycloalkyl,

an optionally substituted C_{6-10} aryl,

an optionally substituted C_{6-10} aryl(C_{1-2} alkyl),

an optionally substituted monocyclic heteroaryl selected from the group consisting of an optionally substituted imidazole, an optionally substituted thiazole, an optionally substituted furan, an optionally substituted thiophene, an optionally substituted pyrrole, an optionally

substituted pyridine, an optionally substituted pyrimidine, an optionally substituted pyrazine, an optionally substituted oxazole and an optionally substituted isoxazole, and

an optionally substituted bicyclic heterocyclyl selected from the group consisting of an optionally substituted , an optionally substituted  and an optionally substituted .

30. The compound of any one of Claims 1-9 or 23-29, wherein when A of Formula (Ib) is substituted, A is substituted with one or more substituents selected from the group consisting of an unsubstituted C_{1-4} alkyl, cycloalkyl, hydroxy, an optionally substituted C_{1-4} alkoxy, halogen, haloalkyl, a haloalkoxy, nitro, amino, mono-substituted amino, di-substituted amino, sulfenyl, alkyoxyalkyl, phenyl, mono-cyclic heteroaryl, mono-cyclic heterocyclyl and aminoalkyl.

31. The compound of any one of Claims 1-9 or 23-30, wherein A of Formula (Ib) is an optionally substituted C_{6-10} aryl.

32. The compound of Claim 31, wherein A of Formula (Ib) is an optionally substituted phenyl.

33. The compound of Claim 32, wherein A of Formula (Ib) is a phenyl substituted with one or more substituents selected from the group consisting of: methyl, ethyl, propyl, butyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, phenoxy, bromo, chloro, fluoro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, N,N-di-methyl-amino, N,N-di-ethyl-amino, N-methyl-N-ethyl-amino, N-methyl-amino, N-ethyl-amino, amino, alkylthio, phenyl, imidazole, morpholinyl, pyrazole, pyrrolidinyl, pyridinyl, piperidinyl, pyrrolidinone, pyrimidine, pyrazine, 1,2,4-oxadiazole, $-(CH_2)_{1-2}-NH(CH_3)$, $-O(CH_2)_2-NH_2$, $-O(CH_2)_2-NH(CH_3)$, $-O(CH_2)_2-N(CH_3)_2$, $-O-(CH_2)_{2-4}OH$, $-O(CH_2)_2OCH_3$, $-O(CH_2)_{1-2}$-morpholinyl, $-O(CH_2)_{1-2}$-triazole, $-O(CH_2)_{1-2}$-imidazole, 

, , , , , , , , ,  and .

34. The compound of Claim 32 or 33, wherein A of Formula (Ib) is a di-substituted phenyl.

35. The compound of any one of Claims 1-9 or 23-30, wherein A of Formula (Ib) is an optionally substituted C_{6-10} aryl(C_{1-2} alkyl) or an optionally substituted monocyclic C_{3-8} cycloalkyl.

36. The compound of any one of Claims 1-9 or 23-30, wherein A of Formula (Ib) is an optionally substituted monocyclic heteroaryl selected from the group consisting of: an optionally substituted imidazole, an optionally substituted thiazole, an optionally substituted furan, an optionally substituted thiophene, an optionally substituted pyrrole, an optionally substituted pyridine, an optionally substituted pyrimidine, an optionally substituted pyrazine, an optionally substituted oxazole and an optionally substituted isoxazole; or an optionally substituted bicyclic heterocyclyl selected from the group consisting of an optionally substituted , an optionally substituted  and an optionally substituted .

37. The compound of any one of Claims 1-9 or 23-36, wherein Y of Formula (Ib) is a substituted phenyl.

38. The compound of any one of Claims 1-9 or 23-36, wherein Y of Formula (Ib) is an optionally substituted mono-cyclic heteroaryl selected from the group consisting of: an optionally substituted imidazole, a substituted furan, a substituted thiophene, an optionally substituted pyrrole, a substituted pyrimidine, an optionally substituted pyrazine, a substituted pyridine, an optionally substituted oxazole and an optionally substituted isoxazole.

39. The compound of any one of Claims 1-9 or 23-36, wherein Y of Formula (Ib) an optionally substituted bi-cyclic heteroaryl selected from the group consisting of an optionally substituted benzothiophene, an optionally substituted benzofuran, a substituted indole, an optionally substituted quinoline, an optionally substituted isoquinoline, an optionally substituted benzooxazole, an optionally substituted benzoisoxazole, an optionally substituted benzoisothiazole, an optionally substituted benzothiazole, an optionally substituted benzoimidazole, an optionally substituted benzotriazole, an optionally substituted 1H-indazole, an optionally substituted 2H-indazole, an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , an optionally substituted , and an optionally substituted .

40. The compound of any one of Claims 1-9 or 23-36, wherein Y of Formula (Ib) is an unsubstituted bicyclic heteroaryl selected from the group consisting of an unsubstituted benzothiophene, an unsubstituted benzofuran, an unsubstituted quinoline, an unsubstituted isoquinoline, an unsubstituted benzooxazole, an unsubstituted benzoisoxazole, an unsubstituted benzoisothiazole, an unsubstituted benzothiazole, an unsubstituted benzoimidazole, an unsubstituted benzotriazole, an unsubstituted 1H-indazole, an unsubstituted 2H-indazole, an

unsubstituted , an unsubstituted , an unsubstituted , an unsubstituted , an unsubstituted , an unsubstituted , an unsubstituted  and an unsubstituted .

41. The compound of any one of Claims 1-9 or 23-36, wherein Y of Formula (Ib) is a substituted bicyclic heteroaryl selected from the group consisting of a substituted benzothiophene, a substituted benzofuran, a substituted indole, a substituted quinoline, a substituted isoquinoline, a substituted benzooxazole, a substituted benzoisoxazole, a substituted benzoisothiazole, a substituted benzothiazole, a substituted benzoimidazole, a substituted benzotriazole, a substituted 1H-indazole, a substituted 2H-indazole, a substituted , a substituted , a substituted , a substituted , a substituted , a substituted , a substituted  and a substituted .

42. The compound of Claim 39, wherein Y of Formula (Ib) is an optionally substituted benzothiophene.

43. The compound of Claim 42, wherein Y of Formula (Ib) is an optionally substituted .

44. The compound of Claim 42 or 43, wherein Y of Formula (Ib) is an unsubstituted benzothiophene.

45. The compound of Claim 42 or 43, wherein Y of Formula (Ib) is a substituted benzothiophene.

46. The compound of Claim 45, wherein the benzothiophene is substituted with one or more substituents selected from the group consisting of halogen, carbonyl, C_{1-4} alkyl, hydroxy, C_{1-4} alkoxy, cyano, amino and mono-substituted amino.

47. The compound of Claim 46, wherein the substituted benzothiophene is .

48. The compound of any one of Claims 1-8 or 10-22, wherein A of Formula (Ic) is selected from the group consisting of:

an optionally substituted C_{3-8} monocyclic cycloalkyl,

an optionally substituted aryl,

an optionally substituted aryl(C_{1-2} alkyl),

an optionally substituted monocyclic heteroaryl selected from the group consisting of an optionally substituted imidazole, an optionally substituted thiazole, an optionally substituted furan, an optionally substituted thiophene, an optionally substituted pyrrole, an optionally substituted pyridine, an optionally substituted pyrimidine, an optionally substituted pyrazine, an optionally substituted oxazole and an optionally substituted isoxazole; and

an optionally substituted bicyclic heterocyclyl selected from the group consisting of an optionally substituted , an optionally substituted  and an optionally substituted .

49. The compound of any one of Claims 1-8, 10-22 or 48, wherein when A of Formula (Ic) is substituted, A is substituted with one or more substituents selected from the group consisting of an unsubstituted C_{1-4} alkyl, cycloalkyl, hydroxy, an optionally substituted C_{1-4} alkoxy, halogen, haloalkyl, a haloalkoxy, nitro, amino, mono-substituted amino, di-substituted amino, sulfenyl, alkyoxyalkyl, phenyl, mono-cyclic heteroaryl, mono-cyclic heterocyclyl and aminoalkyl.

50. The compound of any one of Claims 1-8, 10-22 or 48-49, wherein A of Formula (Ic) is selected from the group consisting of an optionally substituted C_{3-8} monocyclic cycloalkyl and an optionally substituted aryl(C_{1-2} alkyl).

51. The compound of any one of Claims 1-8, 10-22 or 48-49, wherein A of Formula (Ic) is an optionally substituted monocyclic heteroaryl selected from the group consisting of an optionally substituted imidazole, an optionally substituted thiazole, an optionally substituted furan, an optionally substituted thiophene, an optionally substituted pyrrole, an optionally substituted pyridine, an optionally substituted pyrimidine, an optionally substituted pyrazine, an optionally substituted oxazole and an optionally substituted isoxazole; or an optionally substituted bicyclic heterocyclyl selected from the group consisting of an optionally substituted , an optionally substituted  and an optionally substituted .

52. The compound of any one of Claims 1-8, 10-22 or 48-49, wherein A of Formula (Ic) is an optionally substituted aryl.

53. The compound of Claim 52, wherein A of Formula (Ic) is an optionally substituted phenyl.

54. The compound of Claim 53, wherein the phenyl is substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, phenoxy, bromo, chloro, fluoro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, N,N-di-methyl-amino, N,N-di-ethyl-amino, N-methyl-N-ethyl-amino, N-methyl-amino, N-ethyl-amino, amino, alkylthio, phenyl, imidazole, morpholinyl, pyrazole, pyrrolidinyl, pyridinyl, piperidinyl, pyrrolidinone, pyrimidine, pyrazine, 1,2,4-oxadiazole, $-(CH_2)_{1-2}-NH(CH_3)$, $-O(CH_2)_2-NH_2$, $-O(CH_2)_2-NH(CH_3)$, $-O(CH_2)_2-N(CH_3)_2$, $-O-(CH_2)_{2-4}OH$, $-O(CH_2)_2OCH_3$, $-O(CH_2)_{1-2}$-morpholinyl, $-O(CH_2)_{1-2}$-triazole, $-O(CH_2)_{1-2}$-imidazole, , , 

56. The compound of any one of Claims 1-8, 10-22 or 48-55, wherein Y of Formula (Ic) is an optionally substituted phenyl.

57. The compound of Claim 56, wherein Y of Formula (Ic) is a substituted phenyl.

58. The compound of Claim 57, wherein Y of Formula (Ic) is a di-substituted phenyl.

59. The compound of Claim 58, wherein Y of Formula (Ic) is a di-halo substituted phenyl.

60. The compound of any one of Claims 1-8, 10-22 or 48-55, wherein Y of Formula (Ic) is an optionally substituted 

; or an optionally substituted mono-cyclic heteroaryl selected from the group consisting of an optionally substituted imidazole, an optionally substituted furan, an optionally substituted thiophene, an optionally substituted pyrrole, an optionally substituted pyrimidine, an optionally substituted pyrazine, an optionally substituted pyridine, an optionally substituted pyrazole, an optionally substituted oxazole and an optionally substituted isoxazole.

61. The compound of any one of Claims 1-8, 10-22 or 48-55, wherein Y of Formula (Ic) is an optionally substituted bicyclic heteroaryl selected from the group consisting of an optionally substituted benzothiophene, an optionally substituted benzofuran, an optionally substituted indole, an optionally substituted quinoline, an optionally substituted isoquinoline, an optionally substituted benzooxazole, an optionally substituted benzoisoxazole, an optionally substituted benzoisothiazole, an optionally substituted benzothiazole, an optionally substituted benzoimidazole, an optionally substituted benzotriazole, an optionally substituted 1H-indazole, an optionally substituted 2H-indazole, an optionally substituted 

, an optionally substituted 

, an optionally substituted 

, an optionally substituted


, an optionally substituted 
, an optionally substituted 
,
an optionally substituted 
and an optionally substituted 
.

62. The compound of Claim 61, wherein Y of Formula (Ic) is an optionally substituted benzothiophene.

63. The compound of Claim 62, wherein Y of Formula (Ic) is an optionally substituted 
.

64. The compound of Claim 62 or 63, wherein Y of Formula (Ic) is an unsubstituted benzothiophene.

65. The compound of Claim 62 or 63, wherein Y of Formula (Ic) is a substituted benzothiophene.

66. The compound of Claim 65, wherein the benzothiophene is substituted with one or more substituents selected from the group consisting of halogen, carbonyl, C_{1-4} alkyl, hydroxy, C_{1-4} alkoxy, cyano, amino and mono-substituted amino.

67. The compound of Claim 66, wherein the substituted benzothiophene is 
.

68. The compound of Claim 1, wherein the compound is selected from the group consisting of: 
,


,

,

,

,

,

,

,

,

,

,


CF3
Cl
O
H
N
O
N
H
N
N
H


O
H
N
O
N
H
N
N
H


,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,






,

,





,

,

,

,

,

,

,

,

,

,

,

,






O
O
O
H
N
O
N
H
N
S
O


O
O
O
H
N
O
N
H
N
S
F
F





O
O
H
N
O
N
N
S

,


O
O
H
N
O
N
N
S


O
O
H
N
O
N
H
N
S
F

,


O
O
H
N
O
N
H
N
S
F







O
O
H
N
O
N
N
H
NH

,


O
O
H
N
O
N
N
H
S




O
O
O
H
N
O
N
H
N
HN
O
O
S


,

,

,

,

,

,

,

,

,

,


,

,




,



,




,

,



,

,

,

,

,

,

,

,

,

,

,




,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,




and or a pharmaceutically acceptable salt of the foregoing.

69. The compound of Claim 1, wherein the compound is selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,


,

,


and  or a pharmaceutically acceptable salt of the foregoing.

70. The compound of Claim 1, wherein the compound is selected from the group consisting of: , , , , , , ,


HO
O
O
H
N
O
N
S
F
O

,


HO
O
O
H
N
O
N
S
F

,


O
O
H
O
F
S


,

,











,

,

,


,

,

,



,



,



,



,



,



,



,



,



,


,

,



,

,



,

,



,

,







,

,



,

,



HO
O
O
H
N
O
N
F
Cl
O
OH
,

HO
O
O
H
N
O
N
F
Cl
O
OH
,

HO
O
O
H
N
O
N
F


,

,



HO
O
O
H
N
O
O
N
S
F
O

,


O
O
H
N
O
O
N
S
F
O
OH

,


HO
O
O
H
N
O
OH
O
N
Cl
F
,

HO
O
O
H
N
O
OH
O
N
F
Cl
,

HO
O
O
H
N
O
O
N
F
CF3


HO
O
O
HN
O
N
F
Cl
OH

,


HO
O
O
HN
O
N
F
CF3
OH

,


HO
O
O
HN
O
N
F
HO


,

,



,

,



O
O
H
N
O
N
N
F

,


O
O
H
N
O
N
S
F
Cl

,


HO


,

,



,

,



,

,




or a pharmaceutically acceptable salt of the foregoing.

71. A compound selected from the group consisting of:


,

,

,

,

,

,

,

,


O
H
N
O
N
H
N
NH

,


H
N
O
N
H
N
NH
CF3
Cl

,


O
O
H
N
O
N
N
H
NH

,


O
O
H
N
O
N
N
H
N

,







or a pharmaceutically acceptable salt of the foregoing.

72. A pharmaceutical composition comprising an effective amount of a compound of any one of Claims 1-71, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, excipient, or combination thereof.

73. Use of an effective amount of a compound of any one of Claims 1-71, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for ameliorating or treating a paramyxovirus infection.

74. Use of an effective amount of a compound of any one of Claims 1-71, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for inhibiting replication of a paramyxovirus.

75. The use of Claim 73 or 74, wherein the paramyxovirus is a human respiratory syncytial virus.

76. The use of Claim 73 or 74, wherein the paramyxovirus is a human respiratory syncytial virus, and further comprising the use of an effective amount of one or more anti RSV-agents.

77. The use of Claim 76, wherein the one or more anti-RSV agents is selected from the group consisting of ribavirin, palivizumab, RSV-IGIV, ALN-RSV01, BMS-433771, RFI-641, RSV604, MDT-637, BTA9881, TMC-353121, MBX-300 and YM-53403.